Who Owns Regeneron?
Regeneron is the corporate and product brand of Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN), an independent publicly traded biotechnology company headquartered in Tarrytown, New York. No parent company owns the brand. Founded in 1988 by Leonard Schleifer, Regeneron develops medicines including Eylea, Dupixent, and Libtayo and reported $14.3 billion in revenue for fiscal year 2025.
Parent Company
Founded
1988
Status
Publicly Traded
Headquarters
Who Owns Regeneron?
- Parent Company: Regeneron Pharmaceuticals, Inc.
- Ownership Type: Brand division
- Company Type: Publicly Traded
- Stock Ticker: NASDAQ: REGN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Regeneron | Regeneron Pharmaceuticals, Inc. | Brand division |
Where to Buy
Disclosure: We may earn commission from purchases
Regeneron on AmazonAdvertisement
History of Regeneron
- Founded: 1988
- Founders: Leonard Schleifer, George Yancopoulos
Leonard Schleifer, a neurologist at Cornell University Medical College, founded Regeneron in 1988 in Tarrytown, New York. George Yancopoulos joined in 1989 and built its research organization. The original focus on neurotrophic factors failed in the clinic in the 1990s and nearly ended the company.
The recovery came through technology. Regeneron's Trap platform produced Arcalyst, approved in 2008, and then Eylea, approved in 2011 for wet age-related macular degeneration. The VelocImmune mouse platform began generating fully human antibodies at industrial speed, producing a pipeline of monoclonal antibody drugs.
Eylea became the company's first blockbuster. A long-running Sanofi collaboration produced Dupixent in 2017 and Libtayo in 2018, along with Praluent and Kevzara. Dupixent grew into one of the best-selling drugs in the world, with $17.8 billion in global sales recorded by Sanofi in 2025.
In 2020, Regeneron developed the REGEN-COV antibody cocktail for COVID-19 and received FDA emergency authorization. In 2023, the FDA approved Eylea HD, a higher-dose formulation built to extend dosing intervals and defend the retinal franchise against Roche's Vabysmo and emerging biosimilars.
Advertisement
By 2026 the brand's growth drivers had shifted toward Dupixent, Libtayo, and Eylea HD. Third-quarter 2026 revenue of $5.1 billion rose 36% year over year, and newer approvals including Lynozyfic for multiple myeloma expanded the oncology portfolio.
About Regeneron Pharmaceuticals, Inc.
What does Regeneron own?
Regeneron owns and markets its internally developed medicines: Eylea and Eylea HD, Libtayo, Praluent, Kevzara, Arcalyst, Evkeeza, Veopoz, Inmazeb, and Lynozyfic, and shares Dupixent economics with Sanofi. It also owns the VelocImmune antibody platform and the Regeneron Genetics Center.
Is Regeneron publicly traded?
Yes. Regeneron Pharmaceuticals trades on Nasdaq under the ticker REGN and is a member of the S&P 500 index.
Who founded Regeneron?
Leonard Schleifer, a neurologist, founded the company in 1988. George Yancopoulos joined in 1989 and built its research organization. Both men still lead the company as CEO and President/Chief Scientific Officer respectively.
Advertisement
Does Sanofi own part of Regeneron?
No. Sanofi is a collaboration partner, not an owner. Sanofi books global Dupixent and Kevzara sales and shares profits with Regeneron under contract. Sanofi previously held a Regeneron equity stake but sold it in 2020.
Where is Regeneron headquartered?
Regeneron is headquartered in Tarrytown, New York, on the Hudson River north of New York City. Its main manufacturing campuses are in Rensselaer, New York, and Limerick, Ireland.
What is Regeneron's biggest product?
Dupixent is the largest by global sales at $17.8 billion in 2025, though Sanofi records those sales and shares the profit. The largest product Regeneron books directly is the Eylea retinal franchise at $7.9 billion in 2025 global sales.
- Founded: 1988
- Headquarters: Tarrytown, New York, USA
- Company Type: Publicly Traded
- Stock: NASDAQ: REGN
- Revenue: $14.3 billion (FY2025)
- Employees: Approximately 15,000
Where Is Regeneron Made / Based?
- Headquarters: Tarrytown, New York, USA
- Manufacturing / Operations: United States, Ireland
Regeneron Categories & Tags
Regeneron Recalls & Controversies
Copay settlement (2024): Regeneron agreed to pay approximately $34 million to resolve U.S. Department of Justice allegations that it used a third-party foundation to channel copay assistance for Eylea in violation of the False Claims Act. The company did not admit wrongdoing.
Advertisement
Patent litigation: Regeneron has fought extended patent disputes to defend Eylea against biosimilar challengers. Settlement terms permit U.S. aflibercept biosimilar entry beginning in the late 2020s.
Brands Owned by Regeneron Pharmaceuticals, Inc.
Advertisement
Regeneron Ownership: Pros & Cons
Advantages
- +Founder-led management provides scientific and strategic continuity rare at this scale
- +Dupixent and Libtayo growth supplies durable revenue drivers beyond the maturing Eylea franchise
- +Internal discovery platforms produce pipeline without costly licensing deals
- +Owned manufacturing in New York and Ireland supports quality control and margin
- +Strong balance sheet funds R&D and share repurchases at the same time
Considerations
- -Eylea faces sustained Vabysmo and biosimilar competition through the late 2020s
- -The largest product's economics run through the Sanofi collaboration, not direct sales
- -Revenue concentration in four products creates dependence on a small franchise set
- -The 2024 DOJ copay settlement keeps marketing practices under regulatory scrutiny
Frequently Asked Questions About Regeneron
Advertisement
Sources & Further Reading
Competitors to Regeneron
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Adarx Pharmaceuticals | United States | 2019 | Mass market | United states | All Genders | |
| Amgen | USA | 1980 | Market leader | Global | All-ages |
Learn More About Competitors
Healthcare PharmaceuticalsADARx
Owned by ADARx Pharmaceuticals, Inc.
Biotechnology brand of ADARx Pharmaceuticals, the San Diego siRNA company that listed on Nasdaq in September 2026.
biotechnologysirnapharmaceuticals
Healthcare PharmaceuticalsAmgen
Owned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
biotechnologypharmaceuticalsbiologics
Competitive Analysis
Market Positioning: Regeneron competes with 2 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Regeneron
Looking for brands with different ownership structures? These similar brands are not owned by Regeneron Pharmaceuticals, Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsPfizer
Owned by Pfizer Inc.
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
pharmaceuticalvaccinesmedicines
Publicly Traded
Pfizer operates independently without a large parent corporation.
Healthcare PharmaceuticalsAmgen
Owned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
biotechnologypharmaceuticalsbiologics
Publicly Traded
Amgen operates independently without a large parent corporation.
Healthcare PharmaceuticalsGE HealthCare
Owned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
healthcare-technologymedical-imagingdiagnostics
Publicly Traded
GE HealthCare operates independently without a large parent corporation.
Healthcare PharmaceuticalsHCA Healthcare
Owned by HCA Healthcare, Inc.
HCA Healthcare is the flagship brand of the largest U.S. for-profit hospital operator, a network of 190 hospitals and about 2,500 ambulatory sites across 19 states and England.
hospitalshealthcareemergency-care
Publicly Traded
HCA Healthcare operates independently without a large parent corporation.
Healthcare PharmaceuticalsPhilips
Owned by Koninklijke Philips N.V.
Health technology brand owned by Koninklijke Philips N.V., a publicly traded Dutch company listed on Euronext Amsterdam (PHIA). Covers medical imaging, patient monitoring, and personal health products.
healthcare-technologyelectronicsmedical-devices
Publicly Traded
Philips operates independently without a large parent corporation.
Healthcare PharmaceuticalsTirosint
Owned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
levothyroxinehypothyroidismthyroid
Privately Owned
Tirosint is privately owned, unlike Regeneron which is under a publicly traded parent company.
Regeneron Pharmaceuticals, Inc. Stock Information
Advertisement
Jobs at Regeneron Pharmaceuticals, Inc.
Latest News About Regeneron
Advertisement
Related Articles About Regeneron
View more articles
News & Updates
Monthly IPO Roundup: November 2026 -- October's Biggest Listings
October 2026 IPOs: Jio Platforms set India's all-time record at $3.2B and surged 27%, GCash owner Mynt raised a Philippine-record P60.9B, Anthropic filed publicly for a possible mid-November debut, and U.S. listings were a biotech grab bag. Full recap.
Who Brands StaffNov 6, 2026
Ipo RoundupIpoStock Market
News & Updates
Monthly M&A Roundup: October 2026 Brand Ownership Changes
October 2026's biggest deals: Paramount Skydance closed its $110B Warner Bros. Discovery takeover, Salesforce signed Braze for $5.66B, Proofpoint bought Varonis for $6.3B, the Weston family agreed to buy Boots for $8.9B, and Viatris added Pacira for $1.65B. Full breakdown.
Who Brands StaffNov 6, 2026
M And A RoundupAcquisitionsNews
Rivalry
Duracell vs Energizer: The Battery Brand Rivalry
Duracell is Berkshire Hathaway-owned (25-30% US share). Energizer is publicly traded (NYSE: ENR) with Rayovac. Together they control ~85% of branded US batteries, but Amazon Basics has 27.1% online. Explore our database.
Who Brands StaffOct 23, 2026
DuracellEnergizerRivalry
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization
Branddermatology
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription